

Open-label extension trial.

Patients in PRECISE 2 who relapsed before w26 could enter PRECISE 4.

Patients on continuous therapy with certolizumab underwent recapture with a single extra 400mg dose of certolizumab and patients who relapsed after drug interruption underwent reinduction with certolizumab (0,2,4) and then q4w.

Primary endpoint: Clinical response at w4

Results: In PRECISE2, N= 124 patients relapsed & entered PRECISE4

- At week 4 clinical response, 63% in patients who relapsed on continuous therapy with certolizumab and 65% in patients who had drug interruption.
- At week 52, response was maintained in 55% and 59% of these responders respectively.

Conclusion:

Administration of 1 additional dose of certolizumab to patients who relapsed on continuous maintenance therapy, and certolizumab reinduction to those who relapsed after drug interruption, are effective strategies for treating patients who have relapsed after successful induction therapy with certolizumab.




Figure 2. (A) Response rates (reduction from week 0 in HBI score of ≥ 3) and (B) remission rates (HBI score of ≤ 4) in PRECISE 4 (intention-to-treat population).

